Here are the 8-K filings from Apnimed, Inc. (APMD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow APMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APMD filings page.
Apnimed, Inc. (APMD) reported second quarter 2026 results and highlighted major regulatory and financing milestones. The FDA accepted its New Drug Application for AD109 (proposed name Oxnimbi) for obstructive sleep apnea, assigning a PDUFA target action date of February 28, 2027.
For the quarter ended June 30, 2026, Apnimed generated $12.1 million in revenue from a related party and reported net income of $125.9 million, compared with a net loss of $69.5 million a year earlier, driven mainly by a $85.4 million gain on sale of an equity method investment and a $57.1 million gain on reversal of a deposit liability. Research and development expenses fell to $9.9 million, while general and administrative expenses rose to $12.7 million as the company invested in launch preparation for Oxnimbi.
Apnimed reported $172.8 million in cash and cash equivalents as of June 30, 2026, then completed an upsized IPO of 13.8 million shares at $16.00 per share for gross proceeds of $220.8 million. It also entered into a senior secured credit facility of up to $150 million and monetized its interest in Shionogi-Apnimed Sleep Science for $100 million in upfront proceeds, strengthening resources to support potential U.S. commercialization of Oxnimbi.
Apnimed, Inc. amended its corporate governance documents in connection with the consummation of its initial public offering. Immediately prior to the IPO, the company filed a Ninth Amended and Restated Certificate of Incorporation in Delaware, which authorizes 500,000,000 shares of common stock, eliminates all references to previously existing preferred stock series, and authorizes 10,000,000 shares of undesignated preferred stock that the board may issue in one or more series. At the same time, a Second Amended and Restated Bylaws became effective, establishing procedures for stockholder actions and director nominations, including advance notice requirements, and aligning the bylaws with the Restated Certificate.